ELI LILLY & Co Subsidiaries: 148 by Jurisdiction (LLY) | Sharpnel
ELI LILLY & Co (LLY)
NYSE · Common Stock · Pharmaceutical Preparations
One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.
American pharmaceutical company
Corporate structure
148 entities across 48 jurisdictions, 7 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-12 — see the exhibit.
Which other public companies file entities in the same places:
Subsidiaries of ELI LILLY & Co as disclosed in its SEC filing
Entity
Jurisdiction
Note
Adverum Biotechnologies, Inc.
Delaware
Adverum NC, LLC
Delaware
Akouos, Inc.
Delaware
Alnara Pharmaceuticals, Inc.
Delaware
Annapurna Therapeutics, Ltd.
Ireland
Aparito Espanya S.L.
Spain
Aparito Limited
United Kingdom
Aparito LLC
Delaware
ARMO Biosciences, Inc.
Delaware
Avalanche Australia Pty Ltd.
Australia
Avid Radiopharmaceuticals, Inc.
Delaware
Financial health
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
Piotroski F-score
6 / 8
PASSReturn on assets positiveROA 18.4%
PASSOperating cash flow positiveOCF 16.8B
PASSReturn on assets improving13.5% → 18.4%
FAILCash flow exceeds earningsOCF 16.8B vs NI 20.6B
FAILLong-term debt ratio falling36.2% → 36.3% of assets
How many subsidiaries does ELI LILLY & Co file with the SEC?
148, listed in its most recent exhibit 21. They are incorporated across 48 jurisdictions, led by Delaware, Ireland, Spain. 7 of them sit in offshore financial centres. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.
Is ELI LILLY & Co financially healthy?
ELI LILLY & Co scores 6 out of 8 on the Piotroski F-score. Only 8 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of ELI LILLY & Co?
Among the managers tracked here, the biggest positions as of the 2026-Q3 13F filings are BlackRock, Inc. (adding), STATE STREET CORP (adding), FMR LLC (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.
This page is one panel of the terminal
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
CoLucid Pharmaceuticals, Inc.
Delaware
CPD 4, Inc.
Delaware
Dermira, Inc.
Delaware
DICE Alpha Inc.
Delaware
DICE Molecules SV, Inc.
Delaware
DICE Therapeutics, Inc.
Delaware
Disarm Therapeutics Inc.
Delaware
Dista Ilac Ticaret Limited Sirketi
Turkey
Dista, S.A.
Spain
Dista-Produtos Quimicos & Farmaceuticos, LDA
Portugal
ELC EHS, LLC
Indiana
ELCO for Trading and Marketing, S.A.E.
Egypt
ELCO Insurance Company Limited
Bermuda
offshore centre
ELCO Management, Inc.
Delaware
ELGO Insurance Company Limited
Bermuda
offshore centre
Eli Lilly (Malaysia) Sdn. Bhd.
Malaysia
Eli Lilly (S.A.) (Proprietary) Limited
South Africa
Eli Lilly (Singapore) Pte. Ltd.
Singapore
Eli Lilly (Suisse) S.A.
Switzerland
Eli Lilly and Company (India) Pvt. Ltd.
India
Eli Lilly and Company (Ireland) Limited
Ireland
Eli Lilly and Company (N.Z.) Limited
New Zealand
Eli Lilly and Company (Taiwan), Inc.
Taiwan
Eli Lilly and Company Limited
United Kingdom
Eli Lilly Asia Pacific SSC Sdn Bhd
Malaysia
Eli Lilly Asia, Inc.
Delaware
Eli Lilly Australia Pty. Limited
Australia
Eli Lilly Benelux S.A.
Belgium
Eli Lilly Bienes y Servicios S. de R.L. de C.V.
Mexico
Eli Lilly Canada Inc.
Canada
Eli Lilly Clinical Diagnostics Laboratory LLC
Indiana
Eli Lilly Cork Limited
Ireland
Eli Lilly CR s.r.o.
Czech Republic
Eli Lilly Danmark A/S
Denmark
Eli Lilly do Brasil Limitada
Brazil
Eli Lilly Drug Store LLC
United Arab Emirates
Eli Lilly Egypt for Trading Company S.A.E.
Egypt
Eli Lilly European Clinical Trial Services S.A.
Belgium
Eli Lilly Export S.A.
Switzerland
Eli Lilly Finance, S.A.
Switzerland
Eli Lilly Ges.m.b.H.
Austria
Eli Lilly Group Limited
United Kingdom
Eli Lilly Interamerica Inc., y Compania Limitada
Chile
Eli Lilly Interamerica, Inc.
Indiana
Eli Lilly International Corporation
Indiana
Eli Lilly Ireland Holdings Limited
Ireland
Eli Lilly Israel Ltd.
Israel
Eli Lilly Italia S.p.A.
Italy
Eli Lilly Japan K.K.
Japan
Eli Lilly Kinsale Limited
Ireland
Eli Lilly Nederland B.V.
Netherlands
Eli Lilly Norge A.S.
Norway
Eli Lilly Pakistan (Pvt.) Ltd.
Pakistan
Eli Lilly Polska Sp. z.o.o. (Ltd.)
Poland
Eli Lilly Regional Operations GmbH
Austria
Eli Lilly Romania S.R.L.
Romania
Eli Lilly S.A.
Switzerland
Eli Lilly Saudi Arabia Limited
Saudi Arabia
Eli Lilly Services India Private Limited
India
Eli Lilly Services Peru S.A.C
Peru
Eli Lilly Sweden AB
Sweden
Eli Lilly Vostok S.A.
Switzerland
Eli Lilly y Compania de Mexico, S.A. de C.V.
Mexico
Emergence Therapeutics France SAS
France
Glycostasis, Inc.
Delaware
Greenfield-Produtos Farmaceuticos, Lda.
Portugal
ICOS Corporation
Washington
ImClone LLC
Delaware
ImClone Systems Holdings, Inc.
Delaware
Irisfarma S.A.
Spain
Isopro Holdings LLC
Delaware
LDH I Corporation
Delaware
LDH II Corporation
Delaware
LDH III Corporation
Delaware
LDH IV Corporation
Delaware
LDH V 2023 Corporation
Delaware
LDH VI Corporation
Delaware
LDH VII Corporation
Delaware
LDH VIII Corporation
Delaware
Lilly (Beijing) Medical Tech Innovation Co., Ltd.
China
Lilly (Shanghai) Management Co., Ltd.
China
Lilly Asia Ventures Fund I, L.P.
Cayman Islands
offshore centre
Lilly Asia Ventures Fund II, L.P.
Cayman Islands
offshore centre
Lilly Asian Ventures Fund III, L.P.
Cayman Islands
offshore centre
Lilly Cayman Holdings
Cayman Islands
offshore centre
Lilly Centre for Clinical Pharmacology PTE. LTD.
Singapore
Lilly China Research and Development Co., Ltd
China
Lilly del Caribe, Inc.
Cayman Islands
offshore centre
Lilly Deutschland GmbH
Germany
Lilly France S.A.S.
France
Lilly Global Nederland Holdings B.V.
Netherlands
Lilly Global Services, Inc.
Indiana
Lilly Holding GmbH
Germany
Lilly Holdings B.V.
Netherlands
Lilly Hungaria KFT
Hungary
Lilly Ilac Ticaret Limited Sirketi
Turkey
Lilly Japan Financing G.K.
Japan
Lilly Korea Ltd.
Korea
Lilly Lebanon Advanced Therapies LLC
Indiana
Lilly Nederland Finance B.V.
Netherlands
Lilly Nederland Holding B.V.
Netherlands
Lilly Pharma Ltd.
Russia
Lilly Portugal - Produtos Farmaceuticos, Lda.
Portugal
Lilly S.A.
Spain
Lilly Suzhou Pharmaceutical Co. Ltd.
China
Lilly Trading Co. LTD
China
Lilly USA, LLC
Indiana
Lilly Ventures Fund I LLC
Delaware
LillyDirect Pharmacy, LLC
Delaware
Loxo Oncology, Inc.
Delaware
Mablink Bioscience S.A.S.
France
Manet Holdings LLC
Delaware
Morphic Holding, Inc.
Delaware
Morphic Therapeutic UK Ltd.
United Kingdom
Morphic Therapeutic, Inc.
Delaware
NexPharm Parent Holdco, LLC
Delaware
OY Eli Lilly Finland AB
Finland
Pandinus MSC, Inc.
Massachusetts
Petra Pharma Corporation
Delaware
Pharmaserve-Lilly S.A.C.I.
Greece
Point Biopharma Corp.
Canada
Point Biopharma Global Inc.
Delaware
Point Biopharma Inc.
Delaware
Point Biopharma USA Inc.
Delaware
Prevail Therapeutics Inc.
Delaware
Protomer Technologies, Inc.
Delaware
Scorpion Therapeutics, Inc.
Delaware
SGX Pharmaceuticals, Inc.
Delaware
Sigilon Therapeutics Inc.
Delaware
SiteOne Therapeutics, Inc.
Delaware
Spaly Bioquimica, S.A.
Spain
Valquifarma, S.A.
Spain
Versanis Bio Australia PTY LTD
Australia
Versanis Bio, Inc.
Delaware
Verve Therapeutics, Inc.
Delaware
Victoria Holdco Corp.
Delaware
Vitalfarma - Produtos Farmaceuticos, Lda.
Portugal
$65.2B
$20.6B
—
—
899,300,000
BlackRock, Inc.
Index
67,540,400
+1,046,558
$81.0B
MORGAN STANLEY
Active fund
16,226,398
+788,940
$19.5B
STATE STREET CORP
Index
36,215,754
+605,752
$43.4B
Capital World Investors
Active fund
15,902,642
+280,829
$19.1B
GEODE CAPITAL MANAGEMENT, LLC
Index
20,556,572
+245,714
$23.7B
AQR CAPITAL MANAGEMENT LLC
Hedge fund
1,035,605
+180,185
$1.2B
BANK OF AMERICA CORP /DE/
Active fund
11,274,243
+148,411
$13.5B
Point72 Asset Management, L.P.
Hedge fund
76,876
−80,790
$92.2M
PRICE T ROWE ASSOCIATES INC /MD/
Active fund
13,911,839
−80,385
$16.7M
ARK Investment Management LLC
Active fund
77,254
+64,578
$92.7M
RENAISSANCE TECHNOLOGIES LLC
Hedge fund
26,091
−45,697
$31.3M
Bridgewater Associates, LP
Hedge fund
87,023
+16,211
$104.4M
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register. These filings span 2026-Q2–2026-Q3 rather than a single quarter, because filers report on their own schedules.